Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990–2014
Xiang Ren
1, Peng Wu
1, Liping Wang
1, Mengjie Geng, Lingjia Zeng, Jun Zhang, Ningshao Xia, Shengjie Lai, Harry R. Dalton, Benjamin J. Cowling
2, and Sheng Wei
2
Author affiliations: Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China (X. Ren, L. Wang, M. Geng, L. Zeng, S. Lai, H. Yu); World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China (X. Ren, P. Wu, B. Cowling); State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University School of Public Health, Xiamen, China (J. Zhang, N. Xia); University of Southampton, Southampton, UK (S. Lai); Royal Cornwall Hospital and European Centre for Environment and Human Health, University of Exeter, Truro, UK (H.R. Dalton); Fudan University School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China (H. Yu)
Main Article
Figure 1
Figure 1. Annual incidence (solid lines) and mortality rates (dashed lines) of notified hepatitis A (blue) and E (red) cases in China, 1990-2014. The inset shows an enlarged view of rates during 2009–2014. EPI, Expanded Program on Immunization; VCP, virus-like particle.
Main Article
Page created: January 17, 2017
Page updated: January 17, 2017
Page reviewed: January 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.